Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation

Clinical Infectious Diseases

Volumn 47, Issue 7, 2008, Pages 875-882

  San Juan, Rafael ^a   Aguado, José Maria ^a   Lumbreras, Carlos ^a   Fortun, Jesus ^b   Muñoz, Patricia ^c   Gavalda, Joan ^e   Lopez Medrano, Francisco ^a   Montejo, Miguel ^d   Bou, German ^h   Blanes, Marino ⁱ   Ramos, Antonio ^d   Moreno, Asuncion ^f   Torre Cisneros, Julian ^j   Carratalá, Jorge ^g  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL JUAN CANALEJO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT DYSFUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SPAIN;

EID: 52449085831     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591532     Document Type: Article

References (39)

1. San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7:964-71.
2. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(Suppl 7):S754-66.
3. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66:329-37.
4. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68-72.
5. Lumbreras C, Otero JR, Herrero JA, et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37:2490-2.
6. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-5.
7. Nashan B, Luck R, Kliem V, Brunkhorst R, Schlitt HJ, Klempnauer J. CMV in kidney transplantation: a single center experience over 22 years. Clin Transpl 1999:181-8.
8. de Maar EF, Verschuuren EA, Homan vd Heide JJ, et al. Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: a single center report. Transpl Infect Dis 2002; 4:17-24.
9. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645-52.
10. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000; 15:711-4.
11. Moreno-Cuerda VJ, Aguado JM, Morales M, et al. Is double renal transplantation a risk factor for cytomegalovirus disease? Transplant Proc 2005; 37:3764-5.
12. RESITRA. RESITRA definitions, 2004. Available at: http://www.resitra.retics.net/web/index.asp.
13. Torre-Cisneros J, Fortun J, Aguado JM, et al. Documento de consenso GESITRA-SEIMC sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantados. Enferm Infecc Microbiol Clin 2005; 23:424-37.
14. Frei U, Noeldeke J, Machold-Fabrizii V, et al. Prospective age-matching in elderly kidney transplant recipients - a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 2008; 8:50-7.
15. Savoye E, Tamarelle D, Chalem Y, Rebibou JM, Tuppin P. Survival benefits of kidney transplantation with expanded criteria deceased donors in patients aged 60 years and over. Transplantation 2007; 84:1618-24.
16. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33:E62-8.
17. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78:1390-6.
18. San Juan R, Aguado JM, Diaz-Pedroche C, et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006; 82:1457-62.
19. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70:1166-74.
20. Oh CK, Sanfey HA, Pelletier SJ, Sawyer RG, McCullough CS, Pruett TL. Implication of advanced donor age on the outcome of liver transplantation. Clin Transplant 2000; 14:386-90.
21. Grundy JE, Lui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2:132-5.
22. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc 2006; 38:1922-3.
23. Maes BD, Vanrenterghem YF. Cyclosporine: advantages versus disadvantages vis-a-vis tacrolimus. Transplant Proc 2004; 36:40S-9S.
24. Giral M, Nguyen JM, Daguin P, et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001; 12:1758-63.
25. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007; 21:466-71.
26. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7:2522-31.
27. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252-60.
28. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:1070-6.
29. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036-42.
30. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78:35-43.
31. Kudchodkar SB, Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol 2004; 78:11030-9.
32. Ozaki KS, Camara NO, Nogueira E, et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21:675-80.
33. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-4.
34. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41:52-9.
35. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78:1765-73.
36. + T cells in protection against CMV disease. Blood 2003; 101:2686-92.
37. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6:2356-64.
38. Sester U, Sester M, Hauk M, Kaul H, Kohler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1217-23.
39. Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis 2000; 35:611-6.